Similar articles

• Combination chemotherapy in advanced and recurrent Hodgkin's disease.

  McElwain TJ, Wrigley PF, Hunter A, Crowther D, Malpas JS, Peckham MJ, Smithers DW, Fairley GH. McElwain TJ, et al. Natl Cancer Inst Monogr. 1973 May;36:395-402. Natl Cancer Inst Monogr. 1973. PMID: 4744597 No abstract available.
• [Post-MOPP chemotherapy of Hodgkin's disease (author's transl)].

  Osieka R, Bruntsch U, Gallmeier WM, Seeber S, Schmidt CG. Osieka R, et al. Dtsch Med Wochenschr. 1976 Aug 6;101(32):1177-82. doi: 10.1055/s-0028-1104236. Dtsch Med Wochenschr. 1976. PMID: 59661 German.
• [Drug therapy of Hodgkin's disease].

  Gallmeier WM, Bruntsch U. Gallmeier WM, et al. Internist (Berl). 1981 May;22(5):289-300. Internist (Berl). 1981. PMID: 7019138 German. No abstract available.
• Chemotherapy strategies to improve the control of Hodgkin's disease: the Richard and Hinda Rosenthal Foundation Award Lecture.

  Bonadonna G. Bonadonna G. Cancer Res. 1982 Nov;42(11):4309-20. Cancer Res. 1982. PMID: 6181867 Review.
• Advanced Hodgkin's disease: ABVD is better, yet is not good enough!

  Diehl V. Diehl V. J Clin Oncol. 2003 Feb 15;21(4):583-5. doi: 10.1200/JCO.2003.11.072. J Clin Oncol. 2003. PMID: 12586791 Review. No abstract available.